Al Musella
@AlMusellaPres. of the Musella Foundation For Brain Tumor Research & Information, Inc. anything I say here is my own opinion and does not represent the foundation
Similar User
@rago_carlo
@BIO99_BIO99
@Mionaer1
@HenryMuney
@fyre02532
@alphavestcap
@Cheesehammer11
@justinkeister5
@hoffmann6383
@MDendream
@metacollectiveG
@FlemmingBruce
@patrickwalsh14
@Dave46217976
@ATLnsider
Join us TODAY at 5 PM EST for an inspiring event as we come together to champion better treatments and work toward a cure for childhood brain cancer. 💛 👉 Tune in here: facebook.com/share/19Yeb2Ke…
Terminal and rare cancer patients deserve a chance to live. My daughter lost her battle with cancer at age 6 because we had no options. Please join the movement that currently is being considered by the Senate youtube.com/watch?v=_9uCa4… @RobertKennedyJr
An initial study conducted in the Schmainda Lab @MedicalCollege has demonstrated the ability of IB’s FTB maps to be an early predictor of response to Optune treatment for brain tumor patients. A larger study is underway. #Optune #GBM #braintumors #SNO #ASNR #ASFNR
The Musella Foundation Copayment Assistance program is now open! This is for patients with high grade brain tumors, and helps pay for Temodar, Optune, Avastin and Gleostine (and their generics). Details and apply at braintumorcopays.org
Meet our Nurse Navigator from the Brain Cancer Support & Solutions Alliance! Dedicated to guiding patients and families through their brain cancer journey, they offer invaluable support and resources at every step of the way. cancercommons.org/bcssaregistrat… @cancercommons
#IQAI @IQAI_IB with thanks to Shrek1st over on the LSE bb. Excellent publicity for our Expanded Access Program med.unc.edu/neurosurgery/u…
The issue of the brain tumor news blast that we sent out today had a bad link. It is fixed now, but if you clicked on the Advances In Optune article and found an error message, try again. The link is academic.oup.com/oncolo/advance…
Plus Therapeutics presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial evaluating Rhenium (186Re) Obisbemeda at the CNS Annual Meeting yesterday Key Highlights/PR: bit.ly/3Bq8xaR Presentation: bit.ly/3TRJ7Jw #CNS2024 $PSTV
PRESS RELEASE: #𝗕𝗖𝗦𝗦𝗔 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗗𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 #𝗡𝘂𝗿𝘀𝗲𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗼𝗿 𝗳𝗼𝗿 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 #𝗕𝗿𝗮𝗶𝗻𝗖𝗮𝗻𝗰𝗲𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 & 𝗖𝗮𝗿𝗲𝗴𝗶𝘃𝗲𝗿 𝗔𝘀𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 bit.ly/CCBCSSANurse #BrainTumor #NeuroOncology #GBM #DIPG #BTSM
I could use help from my friends in NY State. Write (or call) to our governor, and your state representatives to ask them to support the coverage of Optune for Glioblastomas under Medicaid in NY. See the article below (archive.ph/pxQ1R is a accessible version)
AL MUSELLA: A plea for equity in Medicaid coverage of innovative treatment for glioblastoma newsday.com/opinion/commen…
#BreakingNews Today, the U.S. FDA approved the first targeted therapy for Grade 2 IDH-mutant #glioma – a relentless condition that hasn’t seen treatment advances in nearly 25 years. Learn more about this and Servier’s commitment to patients: ow.ly/yN8j50SRETU
FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation fda.gov/drugs/resource… #OCENewsBurst
Exciting News! Vorasidenib (brand name: Voranigo) has just been approved by the FDA for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation. Read more: braintumor.org/news/exciting-…
Our copayment assistance program is now out of funding and closed to new or renewal applications. I will let you know when it reopens.
The new ratings from Charity Navigator (charitynavigator.org) came out today and they again awarded us their top score of 100% and 4 (out of 4) stars! This is the second year in a row that we received the top score possible!
Data from our positive phase 3 METIS clinical trial, which investigated the use of Tumor Treating Fields therapy in the treatment of brain metastases from non-small cell lung cancer, will be presented today at the @ASCO Annual Meeting in Chicago. #ASCO24 novocure.com/metis-phase-3-…
We have another great webinar tonight: Wednesday May 29, 2024 (7pm EST) IMVAX Phase 2b trial, Dr. Brad Zacharia go to virtualtrials.org/webinar to participate! #gbm
When Brian Wallach was diagnosed with ALS, he was given six months to live. @bsw5020 and @sabrevaya’s film, For Love & Life: No Ordinary Campaign, chronicles their incredible journey, and proves that all of us are far more powerful than we know. I hope you’ll watch it on Prime…
The Promising Pathway Act 2.0 was introduced to Congress yesterday. …-newsnationnow-com.cdn.ampproject.org/c/s/www.newsna…
Webinar now! Starts in a few minutes. Our webinar starts in 10 minutes: virtualtrials.org/webinar Thursday May 23, 2024 (6pm EST) Empowering Brain Tumor Patients - Informed Decision Making, Dr. Isabelle Germano, Dr Kevin Elmore and Dr. Stanislav Lazaev.
United States Trends
- 1. Cowboys 70,6 B posts
- 2. soobin 79 B posts
- 3. Clippers 11,4 B posts
- 4. Norman Powell 1.996 posts
- 5. Texans 54,1 B posts
- 6. Jerry 42,8 B posts
- 7. Cooper Rush 11,8 B posts
- 8. Mike McCarthy 3.266 posts
- 9. sabrina 110 B posts
- 10. Joe Mixon 10,6 B posts
- 11. Lindy 3.657 posts
- 12. Trey Lance 3.207 posts
- 13. Dyson Daniels 2.809 posts
- 14. Keon Ellis 1.711 posts
- 15. Herta 39,5 B posts
- 16. #AskShadow 7.321 posts
- 17. Harden 18,7 B posts
- 18. KADOKAWA 26,2 B posts
- 19. Podz 1.488 posts
- 20. #EeveeDay N/A
Who to follow
-
Carlo Rago, PhD
@rago_carlo -
Bio99
@BIO99_BIO99 -
Mionaer
@Mionaer1 -
Henry
@HenryMuney -
Fireman02360
@fyre02532 -
alphavestcapital.com
@alphavestcap -
Cheesehammer
@Cheesehammer11 -
Justin Keister MS DABR
@justinkeister5 -
hoffmann6383
@hoffmann6383 -
MI Dendream
@MDendream -
Gregory Zivic, MD
@metacollectiveG -
🇩🇰 The Danish Dude 🇩🇰
@FlemmingBruce -
patrick walsh
@patrickwalsh14 -
Hope4Patients
@Dave46217976 -
ATLnsider
@ATLnsider
Something went wrong.
Something went wrong.